Policy Focus: PrEP Could Be A “Game Changer” in Fight Against HIV

By | Health Policy, HIV/AIDS | No Comments
Analysis examines biomedical prevention technology to be reviewed by U.S. Food and Drug Administration by June 15, 2012 Pre-exposure chemoprophylaxis (PrEP)—taking antiretroviral medications to prevent HIV transmission—could be a “game changer” for HIV prevention. PrEP has demonstrated partial efficacy with men who have sex with men (MSM), transgender women, and heterosexuals in several recent studies. Recent modeling of PrEP implementation coupled with scaled up treatment predicts that PrEP could significantly reduce HIV incidence and prevalence. And if PrEP is accompanied by sustained care, behavioral interventions, and safety monitoring, PrEP need not lead to increased sexual risk behavior or drug resistance. 
Read More

World AIDS Day Infographic: PrEP for MSM

By | HIV/AIDS, LGBT Health | No Comments
Click above to view full-size or download as a PDF (4mb) Pre-Exposure Prophylaxis (PrEP) is one of the most promising advances in HIV prevention in recent years. In honor of World AIDS Day, we’ve created this infographic detailing some facts and figures about PrEP. As we’ve covered on this blog, there are many sides to the conversation about PrEP—especially regarding its approval for use in men who have sex with men. We hope this infographic will act as an introduction to the topic and springboard to further discussion—about PrEP and other advances in HIV AIDS. Please feel free to share 
Read More

Open Letter to the FDA and Gilead Sciences: Don’t Hold Up PrEP

By | Health Policy, HIV/AIDS | One Comment
We blogged recently about some of the questions surrounding Pre-Exposure Prophylaxis, or PrEP, a method of HIV prevention that includes prescribing HIV medications to HIV-negative individuals. Now Fenway has signed an open letter to the U.S. FDA and Gilead Sciences, urging them to reconsider plans to combine the approval for a prevention indication for men who have sex with men (MSM) and transgender women who have sex with men in a single filing with heterosexuals. We encourage you to read and share the full text of the letter. Last year the iPrEx trial found that PrEP along with standard prevention 
Read More

New York Times: Questions on PrEP

By | HIV/AIDS | One Comment
Last year, a groundbreaking study (for which the Fenway Institute served as one of two U.S. test sites) showed that taking HIV medicines before becoming infected (known as Pre-Exposure Prophylaxis, or PrEP) greatly reduced the risk of HIV transmission in men who have sex with men. The study, called iPrEx, showed that high-risk individuals who took a single daily tablet containing two widely used HIV medications experienced an average of 43.8 percent fewer HIV infections than those who took a placebo pill. But how and when to put these findings into practice isn’t entirely clear, as this New York Times 
Read More